Table 4 Summary of the eligible studies on SII in predicting survival, treatment response, and diagnosis in patients with ovarian cancer

Nie et al. [85], 2019;

Farolfi et al. [44], 2020;

Ramón-Rodríguez et al. [82], 2022;

OCP: platinum-sensitive recurrent treated with a second-line therapy;

EOCP: underwent primary surgery;

Ovarian peritoneal carcinomatosis: underwent CRS with HIPEC

Predicting survival: OS, PFS

Farolfi et al. [39], 2018

EOCP: in FIGO stage III-IV treated with first-line CT or CTB

Predicting treatment response: efficacy of CT